A new analysis finds that policy and payment gaps are limiting access to diagnostics, with nearly half the world lacking adequate testing and reimbursement lagging behind advances in precision therapies.
Read More
Foundation Medicine will acquire SAGA Diagnostics’ Pathlight MRD platform, expanding its cancer monitoring portfolio. The $595 million deal is expected to close by Q3 2026, with integration supporting treatment selection and recurrence monitoring.
Read More
City of Hope will evaluate Quest Diagnostics’ Haystack MRD liquid biopsy in a multi-year trial, assessing its use for monitoring breast, colorectal, ovarian, and prostate cancers in about 500 patients across 14 US sites.
Read More
The assay predicts both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Read More
A national study in Abu Dhabi used data from 500,000 citizens to improve early detection and prevention of inherited eye diseases.
Read More